Linked Life Data

8398311

Source:http://linkedlifedata.com/resource/pubmed/id/8398311

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1993-11-23
pubmed:abstractText
New photosensitizing drugs are becoming available which should improve on some of the disadvantages of haematoporphyrin derivates for photodynamic therapy (PDT). The main features are shorter duration of systemic photosensitisation, activation by longer and more penetrating light and better tumour to normal tissue drug uptake ratios. These drugs together with better understanding of in vivo light dosimetry promise to improve both results and clinical acceptability for PDT in future studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
29A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1781-3
pubmed:dateRevised
2008-5-30
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
New drugs and future developments in photodynamic therapy.
pubmed:affiliation
Cookridge Hospital, West Yorkshire, U.K.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't